GlassScriptPhysician profile
Sarah Gloria Lain
NPI 1588897532
$2,080.73
in general payments reported to CMS, 2019-2025
16 companies · $360 in 2025
The $360 reported for 2025 was more than what 79% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $107 · 2021: $590 · 2022: $367 · 2023: $250 · 2024: $287 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $364.37 | 2019-2025 | Sublocade, Perseris |
| Otsuka America Pharmaceutical, INC. | $285.79 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $240.63 | 2021-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $193.10 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $160.71 | 2020-2025 | Invega |
| Teva Pharmaceuticals USA, INC. | $159.76 | 2022-2023 | Austedo, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $141.91 | 2020-2022 | |
| Lundbeck LLC | $124.99 | 2021-2025 | Abilify Asimtufii |
| Alkermes, INC. | $122.46 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $78.68 | 2023-2024 | |
| Orexo US, INC. | $70.03 | 2021 | |
| Corium, LLC | $55.88 | 2022-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $31.05 | 2019 | |
| Eisai INC. | $22.89 | 2021 | |
| Ironshore Pharmaceuticals INC. | $15.81 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Lain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.